Alcohol Withdrawal Syndrome

Definition

Alcohol withdrawal syndrome (AWS) is the clinical syndrome that occurs when a person with alcohol dependence or alcohol use disorder (AUD) abruptly reduces or stops alcohol consumption. ^[8]B3b In DSM-5-based clinical research, withdrawal is operationalized by the occurrence of at least two characteristic clinical signs or symptoms after reduction or cessation of heavy and prolonged alcohol use; this definition was used in a cohort of patients entering treatment for AUD. ^[4]B3b Thus, AWS is a syndrome defined by a temporal relationship between reduced alcohol exposure and a characteristic clinical response, rather than by a blood alcohol concentration, an alcohol-related diagnosis code alone, or a history of alcohol use without withdrawal manifestations. ^{[2]B3b[3]B2c[4]B3b}

The term “alcohol withdrawal” is commonly used interchangeably with AWS in clinical and research literature. ^{[1]B3b[3]B2c[5]B2c} However, the reviewed studies use “AWS” in several related but not identical ways: as a DSM-5-based clinical diagnosis, as a clinically recognized inpatient diagnosis identified from administrative codes, as a reason for hospital treatment, and as a protocol-defined condition requiring serial symptom assessment. ^{[3]B2c[4]B3b[6]B3b} These operational differences can affect case ascertainment and reported prevalence. ^[3]B2c

Clinical classification

AWS is best understood as a spectrum of severity rather than a single uniform presentation. ^[1]B3b[5]B2c At the less severe end, patients may have symptoms managed on a general medical ward using symptom-triggered medication protocols. ^{[1]B3b[5]B2c[6]B3b} More severe presentations may require intensive-care management, escalation of sedative therapy, mechanical ventilation, or treatment for delirium tremens (DT). ^{[1]B3b[7]B3b[9]B3b} DT is treated as a severe alcohol-withdrawal presentation in the cited literature, although the supplied studies do not provide a separate diagnostic definition or a universal threshold distinguishing DT from other severe AWS. ^[1]B3b

For treatment and monitoring purposes, the literature distinguishes several practical categories:

• Uncomplicated or protocol-manageable AWS: withdrawal assessed repeatedly with a structured symptom instrument and treated according to symptom severity. ^{[1]B3b[6]B3b[7]B3b}
• Severe AWS: withdrawal associated with substantial agitation, worsening clinical status, need for intensive monitoring, or escalation of pharmacologic treatment. ^[7]B3b[9]B3b
• Delirium tremens: a severe withdrawal diagnosis included alongside AWS in hospital cohorts and treatment-protocol evaluations. ^[1]B3b
• Resistant alcohol withdrawal (RAW): severe withdrawal that does not respond adequately to benzodiazepines despite escalating doses. ^[9]B3b RAW is associated with increased mechanical ventilation, nosocomial pneumonia, and longer ICU stays. ^[9]B3b
• AWS with complications: withdrawal accompanied by clinically important outcomes such as arrhythmias, which are associated with increased mortality in hospitalized AWS populations. ^[120]D

These categories describe clinical severity and management complexity; they should not be interpreted as universally standardized diagnostic subtypes because the cited studies used different inclusion criteria, coding systems, and institutional protocols. ^{[1]B3b[3]B2c[5]B2c[9]B3b}

Nomenclature and related terms

“Alcohol withdrawal syndrome” should be distinguished from alcohol use disorder, which is the underlying disorder associated with recurrent problematic alcohol use, and from alcohol intoxication, which represents a different alcohol-related state. ^[2]B3b[4]B3b A positive blood alcohol level does not by itself establish AWS: in a trauma study, patients were categorized separately according to blood alcohol concentration and AWS status, demonstrating that alcohol exposure and withdrawal were treated as distinct study constructs. ^[2]B3b

“Clinically recognized inpatient AWS” refers to withdrawal documented during hospitalization through diagnosis or procedure codes, rather than necessarily representing a prospectively confirmed syndrome in every case. ^[3]B2c Inpatient AWS may be present on admission or develop later during hospitalization; this distinction was explicitly examined in hospitalized medical-surgical patients. ^[8]B3b

The Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) is an assessment instrument and treatment-monitoring tool, not the definition of AWS. ^[1]B3b[6]B3b Hospital-wide CIWA-Ar protocols and simplified derivatives have been used to guide symptom-triggered benzodiazepine administration. ^[1]B3b[6]B3b CIWA-Ar scores may be difficult to interpret when symptoms have alternative causes. In patients with traumatic brain injury (TBI), AWS and TBI can produce overlapping clinical findings, while benzodiazepines used for AWS may be undesirable in TBI; therefore, a CIWA-based score should not be assumed to prove that symptoms are caused by withdrawal. ^[119]C

The Alcohol Use Disorders Identification Test–Piccinelli Consumption (AUDIT-PC) is a screening instrument studied for prediction of subsequent AWS among hospitalized medical-surgical patients; it is not a diagnostic definition of withdrawal. ^[8]B3b The cited study noted that hospitals require validated approaches to assess withdrawal risk, but that no validated tool was available for that purpose at the time of the study. ^[8]B3b

Practical terminology

“Symptom-triggered,” “fixed-dose,” and “front-loading” describe benzodiazepine treatment strategies, not AWS phenotypes. ^[5]B2c Symptom-triggered protocols use observed withdrawal severity to determine medication administration and have been evaluated in general wards and ICUs. ^{[5]B2c[6]B3b[7]B3b} Conversely, “benzodiazepine-resistant” or “resistant” withdrawal describes inadequate response to treatment, not a separate underlying disease. ^[9]B3b Finally, AWS complicated by arrhythmia, respiratory failure, or need for ICU care should be documented as AWS with a complication or escalation requirement when clinically applicable. ^{[7]B3b[9]B3b[120]D}

Core neuroadaptation

Alcohol withdrawal syndrome (AWS) is characterized clinically by central nervous system hyperexcitation after alcohol exposure is reduced or stopped. ^[22]D5 The principal neurobiological model is an imbalance between inhibitory γ-aminobutyric acid (GABA) signaling and excitatory glutamatergic signaling, with increased N-methyl-D-aspartate (NMDA) glutamate transmission identified as a feature of withdrawal. ^[17]A1b Persistent neuroadaptive changes involving both GABAergic and NMDA systems are also proposed to contribute to symptoms that continue beyond the acute withdrawal period. ^[124]D

This imbalance provides a mechanistic rationale for treatments that enhance GABAergic inhibition or reduce glutamatergic activity. Benzodiazepines remain the standard pharmacological treatment for prophylaxis and management across AWS phases because they provide GABA receptor activity. ^[21]D5[22]D5 Propofol has a complementary pharmacological profile: it agonizes GABA-A receptors at a binding site different from that of benzodiazepines and reduces glutamatergic activity through NMDA receptor blockade. ^[23]D5 These mechanisms are relevant particularly to refractory AWS, although the supporting propofol literature consists of clinical studies, case series, and case reports rather than high-level comparative trials. ^[23]D5

Clinical expression of hyperexcitation

The neuroexcitable state may manifest initially as tremor, sweating, nausea, restlessness, anxiety, and other autonomic or affective symptoms, and can progress to hallucinations, seizures, and delirium tremens. ^{[18]A1b[22]D5} Severe AWS may occur in patients with concomitant medical disease and may require intensive-care management. ^[18]A1b Cardiovascular manifestations reflect altered autonomic regulation: in alcohol-dependent subjects, withdrawal changed the chronotropic and hypotensive responses to propranolol compared with remission, and the investigators attributed these differences to withdrawal-related changes in peripheral and central β-adrenergic systems. ^[19]C4

The response to β-adrenergic blockade is not uniform. Baseline hemodynamics before propranolol administration were the most important modifier of its cardiovascular effects, while the amount of daily alcohol consumption also predicted responses to some extent. ^[19]C4 These findings support the interpretation that autonomic signs are components of a broader withdrawal-related neurophysiological state rather than isolated peripheral abnormalities. ^[19]C4

Acute treatment implications of the neurobiology

GABAergic or otherwise inhibitory agents have been investigated as alternatives or adjuncts to benzodiazepines. Baclofen, a GABA-B agonist, was studied against diazepam in a randomized comparative trial involving 37 patients with AWS; baclofen was administered at 30 mg/day for 10 days, whereas diazepam was tapered over 10 days. ^[15]A1b Multiple Cochrane reviews evaluated baclofen for AWS and described it as a potentially rapidly symptom-reducing, readily manageable treatment with little reported euphoria or drug craving in the reviewed clinical context. ^{[10]A1a[11]A1a[12]A1a[13]A1a[14]A1a} These reviews nevertheless address efficacy and safety assessment rather than establishing baclofen as a replacement for benzodiazepines. ^{[10]A1a[11]A1a}

Other interventions illustrate the distinction between mechanistic plausibility and clinical efficacy. Dextromethorphan is a low-affinity, noncompetitive NMDA antagonist with proposed neuroprotective properties, but a randomized, double-blind, placebo-controlled trial in patients with moderate AWS was specifically conducted because increased NMDA transmission is implicated in withdrawal; its title and preliminary report indicate a lack of efficacy. ^[17]A1b Levetiracetam combined with tiapride was evaluated in an open-label outpatient case series of nine alcohol-dependent patients; all completed treatment, with flexible maximum doses of 2,500 mg/day and 300 mg/day, respectively, for up to seven days. ^[117]C4 This small uncontrolled study supports feasibility rather than a definitive neurobiological treatment effect. ^[117]C4

In severe intensive-care AWS, gamma-hydroxybutyric acid (GHB) and clomethiazole were compared in an open, single-center randomized study of 26 patients with serious withdrawal and medical comorbidity; tremor, sweating, nausea, and restlessness were scored during treatment. ^[18]A1b Dexmedetomidine has been reviewed as an adjunct to benzodiazepine therapy for ICU delirium associated with AWS, reflecting the clinical problem that benzodiazepines may inadequately control delirium when inhibitory and excitatory neurotransmission remain imbalanced. ^[109]A1a Gabapentin has also been examined as a benzodiazepine-sparing strategy, but available evidence includes a retrospective inpatient analysis of a high-dose taper protocol rather than definitive mechanistic proof. ^[122]

Protracted withdrawal and persistent vulnerability

Post-acute or protracted withdrawal is described as a predominantly negative-affect state emerging during early abstinence and potentially persisting for 4–6 months or longer. ^[16]D5 Reported symptoms include anxiety, dysphoria, anhedonia, sleep disturbance, cognitive impairment, craving, and irritability, and these symptoms have been associated with recurrent alcohol consumption. ^[16]D5 A related clinical description emphasizes anxiety, irritability, mood instability, insomnia, and craving that persist beyond expected acute-withdrawal time frames. ^[124]D The proposed persistence of these symptoms is linked to neuroadaptation in GABA and NMDA systems, although protracted withdrawal remains incompletely defined. ^[124]D

Additional hypotheses extend the model. Pyridoxal-5′-phosphate deficiency may impair glutamate-to-GABA conversion through reduced activity of glutamic acid decarboxylase; however, the proposed benefit of repletion for AWS is explicitly a hypothesis rather than established clinical evidence. ^[123]D Preclinical work on sigma-1 receptor antagonists suggests possible effects on alcohol intake, alcohol seeking, cognitive deficits, motor disruption, and relapse-like behavior, but these findings are not yet clinical evidence for AWS treatment. ^[20]D5

Evidence boundaries

The pathophysiological framework supports targeting excessive excitation and deficient inhibition, but treatment responses do not validate every proposed mechanism. ^{[17]A1b[22]D5} Benzodiazepines remain the reference treatment, while baclofen, dexmedetomidine, gabapentin, propofol, GHB, clomethiazole, levetiracetam, tiapride, and other agents have evidence ranging from randomized comparisons and systematic reviews to retrospective studies, case series, and hypotheses. ^{[10]A1a[15]A1b[18]A1b[21]D5[23]D5[109]A1a[117]C4[122][123]D} Accordingly, mechanistic plausibility should not be equated with proven efficacy, particularly for protracted withdrawal and emerging targets such as pyridoxal-5′-phosphate or sigma-1 receptors. ^{[16]D5[20]D5[123]D[124]D}

Epidemiology

Alcohol withdrawal syndrome (AWS) is a clinically important reason for emergency and inpatient care, but its measured frequency varies according to the population studied and the method used to identify cases. A large U.S. electronic-health-record study evaluated emergency-department presentations coded for AWS from 2016 through 2023, using the Epic Cosmos database; the study was designed to quantify the proportion of emergency visits involving AWS, admission rates, length of stay, and medications administered. ^[127] A separate population-based cohort used Kaiser Permanente Washington primary-care records and insurance claims from July 2018 through June 2022 to estimate the incidence and proportional incidence of hospitalizations involving AWS among adults receiving primary care and standardized alcohol screening. ^[128]

Hospital-based estimates are particularly relevant because AWS may be present at admission or develop during hospitalization. The Kaiser Permanente study specifically examined incidence across patient characteristics, underscoring that the observed burden is not uniform across demographic or clinical subgroups. ^[128] AWS was also investigated in specialized or high-risk inpatient populations, including patients hospitalized with alcohol-associated hepatitis (AH), trauma patients, critically ill surgical-trauma patients, psychiatric inpatients, and patients admitted to alcohol-related disease units. ^{[30]B2b[31]B2b[131][135][125]}

In patients hospitalized with AH, the prevalence, predictors, management, and clinical impact of AWS were evaluated retrospectively across five medical centers in Spain and the United States between January 2016 and January 2021. ^[30]B2b This population is clinically important because AWS may complicate admission for severe alcohol-related liver disease; however, the supplied study abstract does not provide the numerical prevalence estimate. ^[30]B2b In Japan, a retrospective study of 88 patients hospitalized with alcoholic hepatitis examined delirium tremens (DT), associated risk factors, and outcomes, reflecting the potential for AWS-related complications to be missed when specialized addiction services are unavailable. ^[40]C4

Sex and age distributions are increasingly being examined rather than assuming that AWS is predominantly a disorder of men. A tertiary alcohol-related disease-unit cohort included 907 patients with alcohol use disorder (AUD), of whom 238 (26.2%) were women, admitted between 2004 and 2022. ^[125] The authors noted that AUD has historically been more prevalent among men and reported sex-specific clinical and psychiatric phenotypes, including AWS manifestations. ^[125] Another hospital cohort included 16,190 hospitalizations representing 10,092 patients, with women comprising 30.2% of the study population; participants were categorized into four age groups: 21–39, 40–64, 65–74, and 75 years or older. ^[36]B2b These data support evaluating AWS risk and presentation across sex and age rather than restricting case recognition to middle-aged men. ^[36]B2b[125]

Etiology and ascertainment

The evidence base supplied here is predominantly observational and focuses on patients already identified as having AWS. Consequently, it describes clinical burden and associated conditions more reliably than population-level causation. ^{[30]B2b[31]B2b[36]B2b[40]C4[125][127][128]} Case ascertainment differed substantially: the AH study used clinical criteria plus sedative use to control AWS symptoms, ^[30]B2b the emergency-department study used relevant ICD-10 codes, ^[127] and hospital protocol studies identified patients through electronic order sets or structured withdrawal assessments such as CIWA-Ar or MINDS-based systems. ^{[6]B3b[130][135]} These differences can change apparent prevalence and may preferentially identify patients with clinically recognized or treated withdrawal. ^{[6]B3b[30]B2b[127][130][135]}

The included literature concerns AWS occurring in the context of AUD or heavy alcohol exposure. In the trauma-center study, “heavy drinking” was operationalized as daily drinking or more than 7 drinks per week, and investigators assessed its relationship with AWS among 1,011 adults admitted to a level I trauma center who had blood alcohol concentration testing. ^[31]B2b The study excluded patients with severe traumatic brain injury defined by a Glasgow Coma Scale score of 8 or less, helping reduce diagnostic overlap between neurologic injury and withdrawal manifestations. ^[31]B2b

Risk factors and high-risk clinical settings

Important risk-assessment settings include trauma, AH, alcoholic hepatitis with possible acute-on-chronic liver failure, psychiatric hospitalization, and critical illness. ^{[30]B2b[31]B2b[40]C4[131][135]} The trauma study was specifically designed to identify combinations of admission conditions that could estimate the probability of AWS, because the proportion of trauma patients developing AWS was considered low and individual risk conditions had not been precisely delineated. ^[31]B2b The Japanese alcoholic-hepatitis study examined DT and other risk factors in a setting where patients may lose contact with care after DT, potentially allowing critical events to be missed. ^[40]C4

Prior AWS-management cohorts also demonstrate that severity is clinically heterogeneous. Studies enrolled patients with moderate-to-severe inpatient AWS, critically ill AWS, or protocol-defined withdrawal, and evaluated outcomes including seizures, DT, severe agitation, pneumonia, intensive-care use, and treatment resistance. ^{[32]A1a[129][131][132]C} A Chinese retrospective study of hospitalized patients with acute AWS examined whether a low sarcopenia index predicted pneumonia, illustrating that frailty and nutritional or muscle-related characteristics may influence complications after AWS has developed; the supplied abstract does not establish that sarcopenia causes AWS itself. ^[132]C Similarly, studies of phenobarbital-resistant AWS evaluated resistance after treatment initiation and therefore address predictors of difficult-to-control withdrawal rather than predictors of developing AWS in the general population. ^[129]

Overall, the strongest recurring epidemiologic signal is concentration of AWS in patients with AUD or heavy alcohol exposure who present to emergency, inpatient, trauma, liver, psychiatric, or intensive-care services. ^{[30]B2b[31]B2b[125][127][128][131][135]} Available studies support systematic screening across sex and age groups and careful differentiation of AWS from trauma, hepatic encephalopathy, infection, medication effects, and other causes of agitation or altered mental status; however, the references supplied do not provide a single validated universal risk score or a definitive causal hierarchy of individual risk factors. ^{[31]B2b[36]B2b[40]C4[128]}

Overview

Alcohol withdrawal syndrome (AWS) is a potentially life-threatening clinical condition that may occur after reduction or cessation of alcohol in a person with chronic, heavy alcohol consumption or alcohol use disorder (AUD). Its severity ranges from mild autonomic and subjective symptoms to seizures, delirium tremens (DT), respiratory complications, and death. ^{[44]A1c[46]A1a} Clinical assessment should therefore consider both current symptoms and the patient’s risk of progression to complicated withdrawal. ^{[50]B2a[93]B2c}

AWS has been described as having acute, early, and protracted phases. Protracted alcohol withdrawal (PAW) may persist for weeks, months, or, in some reports, years after cessation, although the systematic-review evidence most consistently concerns craving and sleep disturbance. ^[47]A1a

Acute and early manifestations

The clinical picture commonly includes anxiety, subjective distress, sleep disturbance, craving, and symptoms of autonomic or neuropsychiatric activation. ^{[47]A1a[61]A1b} Anxiety and depressive symptoms may be prominent during the withdrawal course and have been evaluated serially with standardized anxiety and depression scales in clinical studies. ^[61]A1b Craving generally declines over time after cessation, with pooled obsessive-compulsive drinking scale scores reported to decrease from 24.2 at baseline to 18.8 at 1 week, 10.3 at 1 month, and 9.7 at 3 months. ^[47]A1a

Symptoms may evolve from uncomplicated withdrawal to moderate or severe AWS. In a randomized inpatient trial, participants were considered to have clinically significant withdrawal when their baseline Revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) score was greater than 8. ^[52]A1b In contrast, uncomplicated outpatient AWS has also been studied using CIWA-Ar-based enrollment criteria, demonstrating that the syndrome can be clinically apparent without seizures or delirium. ^[49]A1b

Complicated withdrawal

The principal severe complications are alcohol-related seizures and DT. Severe AWS has been operationalized as a composite of DT, withdrawal seizure, or requirement for high benzodiazepine doses. ^[137] Alcohol-related seizures are an important consequence of AWS and may occur in patients with otherwise variable withdrawal severity; their relationship with DT and overall AWS severity has been specifically examined in a large retrospective cohort and follow-up study. ^[139]C A history of complicated withdrawal, including prior withdrawal seizures or DT, is clinically important when estimating future risk. ^[50]B2a

Risk prediction tools are intended to identify patients likely to develop complicated withdrawal rather than merely quantify symptoms after AWS has begun. The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) was developed because commonly used symptom scales, including CIWA, do not identify in advance which medically ill patients are at risk for complicated AWS. ^[50]B2a The Alcohol Withdrawal Triage Tool (AWTT) was developed to predict severe AWS and hospital-admission need using objective information available during an emergency-department evaluation; its severe-outcome definition included DT, seizure, or high benzodiazepine exposure. ^[137] Machine-learning models have likewise been investigated for predicting moderate-to-severe withdrawal, DT, and withdrawal seizures from admission clinical, laboratory, and sociodemographic variables, although these approaches should not replace clinical judgment. ^[93]B2c

Delirium, cognition, and assessment limitations

DT represents a severe neuropsychiatric manifestation of AWS and should be considered when agitation or altered mental status is accompanied by suspected withdrawal. ^[137][139]C CIWA-Ar scores may be difficult to interpret when symptoms arise from another condition. Traumatic brain injury and AWS can produce overlapping findings, while their treatments differ; use of a CIWA-guided protocol in patients with TBI may consequently lead to administration of central nervous system depressants that are undesirable in TBI. ^[119]C

Alcohol-related illness may also complicate interpretation of mental-status, gastrointestinal, neurologic, and dermatologic findings. Alcoholic pellagra may present with skin lesions, diarrhea, or mental disorders, and the classical triad may be absent, creating potential diagnostic confusion with other alcohol-related diseases. ^[51]C4 Alcohol-associated chronic pain and withdrawal-related changes in pain experience may coexist, and the relationship between AUD and chronic pain can be bidirectional. ^[29]D5

Important alternative diagnoses and comorbidity

Seizures, confusion, fever, headache, or systemic illness should not automatically be attributed to AWS. In a population-based study of alcoholic patients with community-acquired bacterial meningitis, 18% presented with seizures and 23% had co-existing pneumonia; Streptococcus pneumoniae, Listeria monocytogenes, and Neisseria meningitidis were the leading reported organisms. ^[48]B2b Hospitalized patients with acute AWS may also develop pneumonia, and a low sarcopenia index was investigated as a prognostic factor for pneumonia risk. ^[132]C

Clinical evaluation should therefore document the timing and pattern of alcohol reduction or cessation, prior withdrawal complications, current autonomic and neuropsychiatric symptoms, seizure activity, mental status, nutritional and medical comorbidity, and possible mimics. ^{[44]A1c[50]B2a[119]C[137]} Persistent craving, sleep disturbance, anhedonia, anxiety, or depressive symptoms after resolution of acute autonomic findings may represent PAW rather than ongoing severe acute withdrawal. ^{[47]A1a[61]A1b}

Establishing the diagnosis of alcohol withdrawal syndrome (AWS) requires a clinical synthesis of recent cessation or reduction in heavy alcohol use and the emergence of characteristic autonomic and neuropsychiatric symptoms. Because AWS often complicates acute medical admissions, the diagnostic process must simultaneously quantify withdrawal severity and exclude life-threatening organic mimics ^{[27]A1a[30]B2b}.

Clinical Criteria and History

Diagnosis is primarily clinical, based on the presence of at least two symptoms following the reduction of prolonged alcohol intake: autonomic hyperactivity (e.g., sweating, tachycardia), increased hand tremor, insomnia, nausea or vomiting, transient hallucinations, psychomotor agitation, anxiety, or generalized tonic-clonic seizures ^[56]A1c.

Key historical and physical findings that increase the likelihood of progressing to severe alcohol withdrawal syndrome (SAWS) include:

• History of delirium tremens (LR 2.9) ^[27]A1a.
• Baseline systolic blood pressure ≥140 mm Hg (LR 1.7) ^[27]A1a.
• Previous history of AWS (OR 2.09) ^[30]B2b.
• Lower platelet levels (OR 1.61) ^[30]B2b.

Validated Rating Scales

Standardized tools are essential for objective monitoring and to guide symptom-triggered therapy, which has been shown to reduce treatment duration by a mean of 60.4 hours compared to fixed-dose regimens ^[54]A1a.

• CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol - Revised): The gold-standard tool for evaluating AWS severity ^[55]A1a. It assesses 10 signs/symptoms including nausea, tremor, paroxysmal sweats, anxiety, agitation, tactile/auditory/visual disturbances, headache, and orientation ^[60]A1b.
• PAWSS (Prediction of Alcohol Withdrawal Severity Scale): A highly effective tool for identifying patients at high risk for SAWS. A score of 4 or more findings has a likelihood ratio (LR) of 174 and a specificity of 0.93, while a score of 3 or fewer has an LR of 0.07 and a sensitivity of 0.99 ^[27]A1a.
• Wetterling Scale: Used to categorize withdrawal as mild (<6), moderate (6-9), or severe (>9). Higher maximum scores on this scale are independently associated with increased length of stay and in-hospital mortality ^[58]B3b.

Organic Rule-Out and Laboratory Workup

AWS is a diagnosis of exclusion in the setting of altered mental status or seizures. Clinicians must rule out co-occurring conditions that can mimic or exacerbate withdrawal symptoms.

Diagnostic Algorithm

1. Screen for Risk: Utilize the PAWSS tool upon admission for any patient with a history of heavy alcohol use ^[27]A1a.
2. Confirm Cessation: Document the timing of the last drink; symptoms typically emerge within 6-24 hours ^[56]A1c.
3. Baseline Assessment: Obtain vital signs and perform a physical exam focusing on tremors and autonomic hyperactivity ^[27]A1a.
4. Rule Out Mimics: Order CBC (assess for thrombocytopenia), CMP (assess for electrolyte derangements and liver function), and consider CT head or lumbar puncture if focal deficits or fever are present ^{[30]B2b[48]B2b[53]A1c}.
5. Severity Stratification: Initiate serial CIWA-Ar scoring (e.g., every 1-4 hours depending on severity) to guide pharmacological intervention ^{[54]A1a[55]A1a}.

Pearl: A PAWSS score of 4 or more is the most robust predictor of severe withdrawal (LR 174), and its use should trigger aggressive prophylaxis or ICU-level monitoring ^[27]A1a.

Clinical spectrum and course

Alcohol withdrawal syndrome (AWS) is a clinical spectrum that may range from autonomic and neuropsychiatric symptoms to seizures, delirium, and a need for high-intensity monitoring or critical care. ^[65]A1c Severity should be reassessed over time because symptom burden and treatment requirements may change during hospitalization. ^[55]A1a The Clinical Institute Withdrawal Assessment for Alcohol—Revised (CIWA-Ar) is widely used to quantify symptoms and follow their course, although its validity may be limited in patients who cannot reliably communicate, have delirium, or have competing medical or neurologic illness. ^{[55]A1a[65]A1c}

A CIWA-Ar score above 8 was used as an inclusion threshold for hospitalized patients in a multicenter randomized trial of oral magnesium supplementation, illustrating a commonly used boundary for clinically significant withdrawal symptoms rather than a universal definition of severe AWS. ^[52]A1b CIWA-Ar should not be interpreted in isolation: medication exposure, clinical trajectory, vital-sign instability, seizures, hallucinations, delirium, respiratory status, and comorbid disease may be more informative than a single score. ^[65]A1c[144]

Risk stratification before and during withdrawal

The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) is a pre-treatment risk tool intended to identify patients at risk for complicated withdrawal. ^[70]B2b[143] In a randomized hospital-based trial, PAWSS ≥4 defined risk for complicated AWS; 88 adults meeting this criterion were randomized within 16 hours of admission to a fixed-dose gabapentin taper or CIWA-Ar-directed benzodiazepines. ^[70]B2b A hospital screening protocol similarly used universal PAWSS screening, followed by the Glasgow Modified Alcohol Withdrawal Scale (GMAWS) for patients considered at risk. ^[143]

Risk assessment should incorporate prior withdrawal seizures or delirium, heavy or sustained alcohol exposure, recent reduction or cessation, concurrent illness, and the reliability of symptom assessment. ^[65]A1c Trauma populations require particular attention because alcohol-related risk conditions and the probability of AWS have been examined in retrospective cohorts, including a Level I trauma-center study that evaluated heavy drinking, defined as daily drinking or more than seven drinks per week. ^[31]B2b A separate trauma case-control study compared patients by blood alcohol concentration and AWS status to examine associations with hospital outcomes. ^[2]B3b

Patients with liver disease may have a more complicated inpatient course. ^[142] In a retrospective Mayo Clinic Health System cohort, patients with liver disease receiving a CIWA-Ar protocol had longer hospital stays than patients without liver disease: median 93 hours (interquartile range, 51–173) versus 69 hours (43–125). ^[142] Alcohol-associated hepatitis is another clinically important setting in which AWS prevalence, predictors, management, and mortality have been evaluated in a multinational retrospective cohort, although the cited abstract does not provide the numerical prevalence or adjusted predictor estimates. ^[30]B2b

Severe and complicated withdrawal

Complicated AWS includes withdrawal seizures, delirium tremens, severe agitation or autonomic instability, and withdrawal requiring intensive monitoring or escalating sedative therapy. ^{[65]A1c[32]A1a} A multicenter observational study specifically evaluated whether CIWA-Ar scores and benzodiazepine or barbiturate doses identify hospitalized patients requiring high-intensity care. ^[144] The available abstract establishes the study question and population but does not provide a single validated CIWA-Ar or medication-dose cutoff; therefore, fixed thresholds for ICU transfer should not be inferred from this study alone. ^[144]

Pregnancy may be associated with substantial clinical severity, although evidence is sparse. ^[140]C In a retrospective Mayo Clinic series of 8 pregnant patients managed with a CIWA-Ar protocol, the median peak CIWA-Ar score was 17 (interquartile range, 14), and maternal and fetal outcomes were assessed. ^[140]C These data are insufficient to define pregnancy-specific severity thresholds, but they support early specialist assessment and close maternal–fetal monitoring when AWS occurs. ^[140]C

Treatment implications of severity classification

Benzodiazepines remain the principal pharmacologic treatment framework in the 2020 American Society of Addiction Medicine guideline for adults hospitalized with AWS of any severity. ^[65]A1c Phenobarbital is recognized as a possible alternative or adjunct in selected settings, but a systematic review of 20 studies—9 emergency-department and 11 other studies—found that evidence regarding optimal dosing and comparative benefit remains unclear. ^[66]A1a Non-benzodiazepine alternatives have been studied in randomized trials, but the evidence is heterogeneous; one meta-analysis reported benefit favoring gabapentin over chlordiazepoxide and lorazepam, while the cited abstract does not provide complete comparative outcomes. ^[71]A1a

A randomized open-label inpatient trial compared fixed-dose gabapentin with CIWA-Ar-directed benzodiazepines in patients at risk for complicated withdrawal, but gabapentin should not be assumed to prevent seizures or delirium in severe AWS without appropriate monitoring and rescue therapy. ^[70]B2b Rapid systematic-review evidence highlights particular safety, ethical, and legal concerns about administering benzodiazepines or barbiturates for moderate-to-severe AWS through telemedicine or ambulatory care. ^[68]B2a Systematic reviews of anticonvulsants have specifically examined inpatient moderate-to-severe AWS, including symptoms, seizures, delirium tremens, and adverse events, but do not establish anticonvulsants as universal substitutes for benzodiazepines. ^[32]A1a

Adjunctive therapies should not be used to obscure worsening withdrawal. ^[65]A1c A multicenter randomized trial evaluated oral magnesium lactate, providing 426.6 mg/day for up to 15 days in inpatients with baseline CIWA-Ar scores above 8, but the abstract supplied here does not report the primary between-group result. ^[52]A1b Dexmedetomidine has been examined retrospectively for ICU stay, hospital stay, mortality, and readmission, but the available study design does not establish causality or a severity threshold for its use. ^[69]B3b

Longer-term course and evidence limitations

Physical withdrawal signs may resolve while neurocognitive, sleep, and brain-related abnormalities persist during early abstinence. ^[146]C In one study, patients were assessed 4–21 days after cessation, when they no longer exhibited physical signs such as nausea, tremor, or anxiety; reported sleep, brain, and cognitive alterations were heterogeneous. ^[146]C Sex-specific differences, pregnancy, liver disease, trauma, and alcohol-associated hepatitis remain areas in which available evidence is predominantly retrospective or limited in sample size. ^{[30]B2b[31]B2b[125][140]C[142]} A study of 907 hospitalized patients with alcohol-related disease included 238 women and examined sex-related clinical and psychiatric phenotypes, but the supplied abstract does not provide sufficiently complete results to define sex-specific AWS severity thresholds. ^[125] A separate ICU study excluded AWS from its analysis and therefore does not inform AWS severity stratification. ^[141]C

Immediate assessment and disposition

Alcohol withdrawal syndrome (AWS) is a potentially life-threatening emergency requiring early assessment of autonomic instability, altered mental status, seizures, delirium, coexisting medical illness, intoxication or poisoning, nutritional deficiency, and risk related to alcohol use disorder (AUD). ^[44]A1c Emergency-department (ED) management should combine withdrawal-severity assessment with evaluation for alternative or concurrent diagnoses rather than relying on a withdrawal score alone when the patient is delirious, sedated, cognitively impaired, or unable to communicate reliably. ^[44]A1c The 2024 Society for Academic Emergency Medicine GRACE-4 guideline was developed specifically for adult ED patients with AWS and AUD using the GRADE framework and included emergency physicians, addiction-medicine specialists, and people with lived experience. ^[44]A1c

Patients with delirium tremens, severe autonomic activation, recurrent or uncontrolled withdrawal seizures, respiratory compromise, significant metabolic or infectious illness, or inability to maintain safety require monitored treatment and consideration of hospital or intensive-care admission. ^[44]A1c Delirium tremens is a serious AWS complication, and biomarker research continues to investigate inflammatory, biochemical, hematological, and gut-permeability differences between severe AWS with delirium tremens and mild or moderate AWS. ^[148] A 2025 United States ED study was designed to quantify AWS presentations, admission, length of stay, and medication use from 2016–2023, reflecting the substantial and increasing operational burden of AWS care. ^[127]

Pharmacological treatment of acute withdrawal

Benzodiazepines remain the established first-line pharmacotherapy for AWS, particularly when the objective is prevention or treatment of withdrawal seizures and delirium. ^[73]A1a Treatment should be titrated to clinical response with frequent reassessment of mental status, respiratory rate, oxygenation, blood pressure, heart rate, and withdrawal severity; excessive sedation and respiratory depression are important treatment hazards. ^[44]A1c

Phenobarbital is an alternative or adjunct when benzodiazepines are unavailable, insufficient, or unsuitable, but dosing strategies and the optimal role of phenobarbital remain uncertain. ^[66]A1a A 2023 systematic review identified direct ED evidence comparing phenobarbital with benzodiazepines or no intervention, examining symptom control, complications, monitored-setting admission, adverse effects, and need for adjunctive medication. ^[74]A1a A 2024 systematic review and meta-analysis evaluated randomized and cohort studies comparing phenobarbital with benzodiazepine treatment and concluded that the ED evidence should be interpreted in the context of mixed safety and efficacy findings. ^[73]A1a Phenobarbital should therefore be administered by clinicians experienced with its prolonged sedative effect, with appropriate respiratory and hemodynamic monitoring, particularly when it is combined with benzodiazepines. ^{[73]A1a[74]A1a}

A 2025 single-center retrospective cohort of 1,178 adults compared intravenous phenobarbital monotherapy, intravenous benzodiazepines, and combination therapy for ED AWS; outcomes included admission, ED length of stay, and 72-hour return visits. ^[113]B3b Because this was observational evidence, its findings should not be interpreted as proof that phenobarbital is superior to benzodiazepines. ^[113]B3b A multicenter ICU study published in 2026 evaluated phenobarbital use, treatment escalation, discharge timing, and safety after propensity matching in adults with AWS defined by a CIWA-Ar score of ≥10; phenobarbital use in that setting may identify severe or refractory withdrawal rather than represent a comparable treatment choice for uncomplicated AWS. ^[171]

Gabapentin may reduce withdrawal symptoms or benzodiazepine exposure in selected hospitalized patients, but evidence is limited: a 2022 meta-analysis included eight retrospective studies involving 2,030 patients and found no randomized studies. ^[75]A1a Gabapentin should not replace benzodiazepines for severe AWS, delirium, or seizure-risk states on the basis of current evidence. ^[75]A1a

Baclofen and vigabatrin remain investigational or adjunctive approaches rather than standard emergency therapy. ^{[77]A1b[78]A1b} In a single-blind randomized trial of 63 inpatients, baclofen at 30 or 60 mg/day for 7 days was compared with placebo during benzodiazepine-assisted detoxification, with diazepam supplied according to withdrawal symptoms; the investigators stated that available evidence was insufficient to support baclofen-assisted withdrawal as routine care. ^[77]A1b A double-blind randomized trial enrolled 120 residential-treatment patients to vigabatrin 2 g/day for 4 days or placebo and assessed the need for diazepam and total diazepam exposure; these findings do not establish vigabatrin as standard ED treatment. ^[78]A1b

Oral ethanol prescribing has been reported in selected United Kingdom acute-care settings for patients considered at high risk of delirium tremens, with harmful consumption typically ≥30 units/day, or with previous severe withdrawal, withdrawal seizures, or delirium tremens. ^[147]C This retrospective experience is not sufficient to recommend ethanol as routine ED treatment, and benzodiazepine-based protocols remain the better-supported standard. ^[147]C

Psychiatric emergencies and post-acute symptoms

Acute confusion, agitation, hallucinations, or behavioral disturbance should be treated as possible delirium or severe withdrawal until dangerous medical causes have been assessed; sedating medication must be balanced against respiratory depression and the risk of obscuring neurological deterioration. ^[44]A1c[148] After the acute phase, protracted withdrawal can include anxiety, dysphoria, anhedonia, irritability, cognitive impairment, sleep disturbance, and craving, with negative affect potentially persisting for 4–6 months or longer. ^[16]D5 A 2023 systematic review found that pooled craving scores declined over time, from 24.2 at baseline to 18.8 at 1 week, 10.3 at 1 month, and 9.7 at 3 months, although persistent symptoms may increase relapse vulnerability. ^[47]A1a Discharge planning should therefore include assessment of mood, cognition, sleep, craving, relapse risk, psychosocial safety, and access to AUD treatment. ^{[16]D5[47]A1a}

Percutaneous auricular vagus-nerve stimulation has only pilot-level evidence: an open-label, single-arm study enrolled 30 patients with AWS and examined autonomic responses during stable medication treatment. ^[76]B2b It should not be considered established acute treatment. ^[76]B2b

Practical priorities

1. Stabilize airway, breathing, circulation, glucose, temperature, and nutrition while investigating alternative causes of delirium or seizures. ^[44]A1c
2. Use benzodiazepines as first-line therapy for clinically significant AWS and escalate monitoring when symptoms are severe, atypical, refractory, or complicated by delirium or seizures. ^{[44]A1c[73]A1a}
3. Consider phenobarbital only within a monitored, protocolized setting and recognize that comparative ED evidence remains mixed. ^{[73]A1a[74]A1a}
4. Treat psychiatric symptoms as part of a medical emergency: assess capacity, agitation, delirium, self-harm risk, and the safety of discharge before disposition. ^{[44]A1c[16]D5}
5. Link every medically stabilized patient to ongoing AUD care because craving, sleep disturbance, negative affect, and cognitive symptoms may persist after acute withdrawal resolves. ^{[16]D5[47]A1a}

Scope and treatment priorities

The evidence supplied for this section primarily concerns pharmacological management of acute alcohol withdrawal syndrome (AWS), rather than psychotherapy, relapse-prevention pharmacotherapy, or somatic/neuromodulation treatments for established alcohol use disorder (AUD). Accordingly, these interventions should be considered adjunctive or acute-withdrawal strategies, not definitive treatment for the underlying disorder. Definitive care should be linked to AUD treatment planning after withdrawal stabilization; the supplied references specifically document that hospitalization can provide an opportunity to prescribe medications for AUD, while also identifying disparities in discharge prescribing by race, ethnicity, and language. ^[37]B2b

Pharmacotherapy during and after withdrawal

Benzodiazepines remain the comparator or standard treatment in most of the supplied studies. A network meta-analysis of 41 studies involving 4,187 participants found no significant difference in CIWA-Ar reduction between benzodiazepines and the other evaluated medications or medication combinations. The analysis did, however, find that anticonvulsants plus benzodiazepines reduced ICU length of stay by a mean of 1.71 days compared with benzodiazepines alone (95% CI, −2.82 to −0.59 days). ^[57]A1a

Phenobarbital is a potential alternative or adjunct in severe AWS, but should be used with close monitoring because barbiturates and benzodiazepines both produce substantial sedation. In a randomized emergency-department trial, a single intravenous phenobarbital dose of 10 mg/kg added to a standardized lorazepam protocol was evaluated for its effect on ICU admission. ^[85]A1b A systematic review of seven clinical studies compared barbiturates with benzodiazepines using outcomes including delirium duration, seizures, ICU and hospital length of stay, cumulative sedative doses, and respiratory or cardiac complications; the evidence supports consideration of barbiturates in acute-care AWS but does not establish universal superiority over benzodiazepines. ^[45]A1a More recent observational studies reported fewer admissions and shorter stays with phenobarbital monotherapy than with benzodiazepines or combination therapy, ^[113]B3b and examined phenobarbital combined with benzodiazepines for time to AWS resolution and safety outcomes. ^[126] In another retrospective comparison, phenobarbital plus lorazepam was compared directly with dexmedetomidine plus lorazepam for hospital and ICU length of stay, mechanical ventilation incidence, and ventilation duration. ^[114]B3b

Dexmedetomidine may reduce adrenergic symptoms and benzodiazepine exposure but does not replace treatment directed at the underlying withdrawal neurobiology. In a matched ICU cohort, early dexmedetomidine was evaluated for its effect on 12- and 24-hour benzodiazepine requirements, symptom control, ICU and hospital length of stay, mechanical ventilation, bradycardia, and hypotension. ^[87]B3b In nonintubated patients requiring continuous infusion, a retrospective comparison evaluated dexmedetomidine against continuous benzodiazepines for respiratory distress and other clinical outcomes. ^[173] These retrospective data should not be interpreted as proof of superiority, and hemodynamic adverse effects remain clinically relevant. ^[87]B3b

For benzodiazepine-resistant AWS, defined in one healthcare-system study as requiring at least 40 mg of diazepam within 1 hour, dose escalation with or without propofol has been evaluated retrospectively. ^[150]C Propofol is therefore a highly monitored rescue or ICU strategy rather than routine therapy. Observational data also describe patients treated with high-dose intravenous sedatives without routine immediate intubation, with pneumonia and endotracheal intubation as important outcomes. ^[138]C

Other pharmacological options have weaker or more limited evidence. A randomized study of baclofen versus chlordiazepoxide in 60 participants with uncomplicated AWS assessed CIWA-Ar control, with lorazepam available as supplemental treatment when symptoms were inadequately controlled. ^[88]B2b A systematic review and meta-analysis found that tiapride plus carbamazepine significantly reduced AWS symptoms (p<0.0001; z=4.07), but this combination remains an alternative strategy rather than an established replacement for benzodiazepines. ^[80]A1a Oral magnesium lactate supplementation, providing 426.6 mg/day for up to 15 days, was tested as adjunctive treatment in a multicenter randomized trial of inpatients with baseline CIWA-Ar scores greater than 8. ^[52]A1b Intranasal oxytocin was evaluated in a double-blind randomized trial of 40 patients receiving symptom-triggered oxazepam; the study examined whether oxytocin reduced benzodiazepine requirements during a three-day detoxification period. ^[81]A1b

Evidence does not support several proposed substitutes. Dextromethorphan, an NMDA antagonist, failed to demonstrate efficacy in a randomized placebo-controlled trial of patients with moderate AWS and CIWA-Ar scores greater than 10. ^[17]A1b Ethanol-based prevention or treatment has only limited evidence: a pilot randomized study compared lorazepam with ethanol plus lorazepam in 57 patients with myocardial infarction, ^[84]A1b while a retrospective NHS review evaluated oral ethanol in patients at high risk for delirium tremens, heavy consumption, or severe withdrawal. ^[147]C Sodium oxybate has post-marketing and clinical safety data in AUD, including three recent randomized studies involving 520 participants and 43 earlier studies involving 2,547 participants, but these data address safety experience rather than establishing it as routine AWS or definitive AUD therapy. ^[83]D5

Psychotherapy and somatic therapies

None of the supplied references directly evaluates psychotherapy, electroconvulsive therapy, repetitive transcranial magnetic stimulation, transcranial direct-current stimulation, vagus-nerve stimulation, or other neuromodulation interventions as definitive treatment for AWS or AUD. These modalities therefore cannot be recommended or ranked from the evidence provided. The available evidence supports integrating withdrawal treatment with a subsequent AUD plan, including consideration of medication prescribing at discharge, rather than treating detoxification alone as definitive management. ^[37]B2b

Safety and implementation

Severe or refractory AWS requires a setting capable of frequent clinical assessment and cardiorespiratory monitoring. Studies of dexmedetomidine specifically monitored bradycardia and hypotension, ^[87]B3b while barbiturate, propofol, and high-dose sedative studies evaluated mechanical ventilation, respiratory complications, pneumonia, and intubation. ^{[45]A1a[85]A1b[114]B3b[126][138]C[150]C} Ethanol prescribing, phenobarbital protocols, and non-benzodiazepine combinations should therefore be restricted to experienced services using explicit protocols and rescue pathways. ^{[113]B3b[126][147]C}

Bottom line

Benzodiazepines remain the principal evidence-based acute treatment comparator. Phenobarbital, anticonvulsant combinations, baclofen, tiapride–carbamazepine, magnesium, oxytocin, dexmedetomidine, propofol, ethanol, and sodium oxybate have evidence ranging from randomized trials to retrospective or safety studies, but none is established by the supplied references as a universal definitive treatment. Long-term management should focus on AUD-directed follow-up and equitable discharge prescribing, while psychotherapy and neuromodulation require evidence not represented in this reference set. ^{[37]B2b[57]A1a}

Transitioning from acute pharmacological stabilization to a maintenance or adjunctive regimen requires a structured surveillance engine to mitigate iatrogenic harm. While benzodiazepines remain the cornerstone of treatment, the introduction of antipsychotics, antibiotics , or vasoactive agents in the context of alcohol withdrawal syndrome (AWS) necessitates rigorous monitoring of cardiac and metabolic parameters to prevent life-threatening arrhythmias ^[92]C4.

Cardiac and Electrophysiological Surveillance

Patients undergoing treatment for AWS frequently possess multiple risk factors for proarrhythmic responses, including electrolyte disturbances and autonomic instability. The risk of torsade de pointes is significantly elevated when QT-prolonging agents are administered to patients with underlying metabolic derangements ^[92]C4.

• ECG Monitoring: Baseline and serial 12-lead ECGs are required when using adjunctive antipsychotics or when the patient has comorbid conditions (e.g., HIV, chronic liver disease).
• QT Interval Assessment: A prolonged QT interval can be exacerbated by the concomitant use of antibiotics (e.g., piperacillin / tazobactam , metronidazole ) and vasoactive support such as dopamine ^[92]C4.
• Electrolyte Optimization: Aggressive correction of hypokalaemia and hypomagnesemia is mandatory, as these deficiencies lower the threshold for ventricular arrhythmias during the withdrawal state ^[92]C4.

Autonomic and Hemodynamic Monitoring

Pharmacological management must be balanced against the patient's fluctuating autonomic tone. Surveillance should focus on the following parameters:

• Heart Rate: Monitoring for sinus bradycardia or compensatory tachycardia, which may signal either over-sedation or worsening withdrawal ^[92]C4.
• Blood Pressure: Assessment for hypotension, particularly when using agents that modulate alpha-adrenergic or dopaminergic pathways ^[92]C4.
• Rhythm Analysis: In high-risk patients, 24-hour Holter monitoring or continuous telemetry may be necessary to detect self-terminating episodes of torsade de pointes or frequent ventricular premature complexes ^[92]C4.

Metabolic and Hematologic Surveillance

For patients transitioned to long-term psychiatric stabilizers or those requiring clozapine or anticonvulsants, a protocolized monitoring schedule is essential to track metabolic and hematologic health. This includes regular metabolic panels to screen for drug-induced dyslipidemia or glucose intolerance, and complete blood counts for patients on agents with known marrow toxicity.

ECG Findings in AWS Management

Pearl: Hospitalized patients with AWS often have multiple silent risk factors for proarrhythmic responses; always review the medication profile for QT-prolonging drugs and correct even mild hypokalaemia immediately to prevent torsade de pointes ^[92]C4.

Purpose and risk stratification

Alcohol withdrawal syndrome (AWS) develops after abrupt reduction or cessation of alcohol intake in a person with alcohol dependence, and hospitalized patients may deteriorate after admission rather than present with withdrawal initially ^[8]B3b. Severe alcohol withdrawal syndrome (SAWS) is generally defined by delirium tremens, withdrawal seizure, or clinically diagnosed severe withdrawal; it is associated with substantial morbidity and mortality when untreated ^[27]A1a. Because most patients at risk do not develop SAWS, assessment should distinguish exposure to risk from the probability of severe complications ^[27]A1a.

Admission assessment should document recent alcohol consumption, the timing and amount of the last drink, previous withdrawal episodes, seizures, delirium tremens, and relevant medical or neurological disease. These domains are supported by studies evaluating clinical predictors and risk tools, although the available evidence is heterogeneous and some tools were developed in selected inpatient populations ^{[27]A1a[50]B2a[151]}. A history of structural brain lesions was an independent predictor of withdrawal seizures in a cohort of 827 inpatients treated for AWS ^[151]. A delayed peak in withdrawal severity after admission was also associated with seizures, with an odds ratio of 1.23 per 10-hour delay ^[151]. These findings support continued observation even when symptoms are initially mild ^[151].

Screening tools and predictive limitations

The Alcohol Use Disorders Identification Test–Piccinelli Consumption (AUDIT-PC) was evaluated retrospectively in hospitalized medical-surgical patients outside intensive care to determine whether admission alcohol-use screening predicted subsequent AWS; the study specifically addressed patients who presented with AWS and those who developed it later during admission ^[8]B3b. It should therefore be regarded as an admission screening aid rather than a definitive severity or disposition tool ^[8]B3b.

The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) was developed because instruments such as the Clinical Institute Withdrawal Assessment for Alcohol (CIWA) quantify current withdrawal severity but were not designed to identify patients at risk before symptoms emerge ^[50]B2a. The original report described the absence of validated prediction tools in medically ill patients at that time and combined clinical factors into a prediction instrument, with pilot validation rather than definitive broad validation ^[50]B2a. PAWSS should consequently complement, not replace, clinical assessment and serial reassessment ^[50]B2a.

A systematic review assessed the accuracy and predictive value of symptoms, signs, and risk-assessment tools for SAWS in adults hospitalized for medical or surgical care ^[27]A1a. Machine-learning models have also been studied using admission clinical, blood-derived, and sociodemographic variables in two detoxification wards comprising 389 and 805 patients; models attempted to predict moderate-to-severe withdrawal, delirium tremens, and withdrawal seizures, but their performance was described as significant yet limited in separating mild from more severe withdrawal ^[93]B2c. These models remain adjunctive and should not be treated as independently validated bedside disposition rules ^[93]B2c.

Therapeutic setting and monitoring intensity

The setting should match the anticipated risk, current physiological stability, ability to observe the patient, and capacity to deliver rapid treatment. General-hospital protocols have incorporated alcohol-use screening, risk stratification to guide fixed-dose versus symptom-triggered benzodiazepine treatment, a withdrawal scale, and explicit management recommendations ^[152]D. However, the suitability of any protocol depends on local staffing, nursing observation, monitoring capability, and clinician familiarity with the assessment instrument ^[152]D.

Intensive-care practice is variable: in a survey of UK ICU lead consultants, most responding units used weekly alcohol volume to assess alcohol use, while only a minority used the Clinical Institute Withdrawal Assessment approach ^[174]D. This variation emphasizes the need for a clearly defined local pathway, particularly when withdrawal coexists with critical illness, sedation, mechanical ventilation, delirium, or other causes of altered mental status ^[174]D. A patient with suspected SAWS, recurrent seizure, delirium, severe autonomic instability, escalating sedative requirements, or inability to participate reliably in assessment requires a setting capable of continuous observation and rapid airway, cardiovascular, and neurological support ^[27]A1a[151].

Capacity, safety, and disposition

Capacity should be assessed at the time of treatment decisions and revisited when withdrawal fluctuates. Delirium, intoxication, seizure activity, or severe withdrawal may make symptom reporting and informed consent unreliable; the risk of SAWS and its high untreated mortality justify urgent clinical evaluation rather than waiting for a patient to provide a complete history ^[27]A1a. Documentation should record the patient’s understanding of the proposed assessment and treatment, ability to communicate a choice, and the effect of fluctuating cognition on decisions. Patients unable to participate safely in symptom-triggered assessment should not be managed solely through an unobserved or low-monitoring pathway ^{[50]B2a[152]D}.

Nonmedical environments require particular caution. Research in police custody found substantial morbidity and imperfect performance of existing screening procedures, with sensitivity and specificity of 70% and 66% for triggering contact with a healthcare professional regardless of the reason ^[96]B2b. Alcohol-related risk may therefore be missed by generic custody screening, and suspected withdrawal should prompt qualified medical assessment rather than reliance on administrative screening alone ^[96]B2b.

Pregabalin has been reviewed as a possible treatment for alcohol dependence, but the cited review describes limited pharmacological options and an emerging, rather than definitive, evidence base; it does not establish pregabalin as a replacement for a monitored AWS pathway ^[94]D5. Similarly, a retrospective microsurgical series involving patients with alcohol-induced mental disorders concerns surgical reconstruction outcomes and does not provide evidence for AWS risk stratification or therapeutic setting ^[95]B3b.

From supportive care to benzodiazepine-centered treatment

Alcohol withdrawal syndrome (AWS) reflects neuroadaptation to prolonged alcohol exposure, including reduced inhibitory GABAergic activity and increased excitatory glutamatergic activity; withdrawal therefore produces a spectrum ranging from autonomic and subjective symptoms to seizures and delirium. ^[56]A1c Up to half of people who stop drinking after prolonged high-dose alcohol use may develop AWS. ^[56]A1c Historically, treatment evolved around replacing or augmenting deficient inhibitory signaling, with benzodiazepines becoming the usual pharmacologic treatment because they address withdrawal symptoms and are used to prevent severe complications such as seizures and delirium tremens. ^[70]B2b Contemporary reviews continue to describe benzodiazepines as the typical standard against which alternative strategies are compared. ^[102]A1a

The modern approach increasingly emphasizes structured assessment, severity-based treatment, and risk stratification rather than medication alone. The 2020 American Society of Addiction Medicine (ASAM) guideline applies to adults hospitalized with AWS of any severity and represents an update from the society’s 2004 guideline, which focused on alcohol withdrawal delirium. ^[65]A1c Emergency-department guidance subsequently used the GRADE framework to address adult ED management of AWS, alcohol use disorder, and related presentations. ^[44]A1c Risk assessment has also become more explicit: the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) was used to define risk of complicated withdrawal in a randomized hospital trial at a threshold of PAWSS ≥4. ^[70]B2b Machine-learning research has attempted to predict moderate-to-severe withdrawal, delirium tremens, and withdrawal seizures from admission-level clinical, laboratory, and sociodemographic data, although such tools remain an adjunct to clinical assessment. ^[93]B2c

Adjunctive and alternative pharmacotherapy

As treatment evolved, drugs targeting GABAergic, glutamatergic, and autonomic pathways were investigated to reduce benzodiazepine exposure or address difficult-to-control symptoms. Gabapentin, already supported as an outpatient alternative, was evaluated in hospitalized AWS in an open-label randomized trial of 88 adults at elevated risk of complicated withdrawal; participants received either a fixed-dose gabapentin taper or CIWA-directed benzodiazepines. ^[70]B2b A separate randomized clinical trial assigned 68 adults with alcohol use disorder and a history of AWS to gabapentin 1,200 mg/day or placebo after at least 72 hours of abstinence, while measuring dorsal anterior cingulate GABA and glutamate with proton MR spectroscopy. ^[97]A1b These studies reflect the expansion of treatment research beyond acute symptom suppression toward neurobiologic mechanisms and relapse-related outcomes. ^[97]A1b

Baclofen, a GABA-B agonist, has been studied as an alternative or adjunct to benzodiazepines. In a single-blind, dose-dependent randomized trial, 63 inpatients undergoing benzodiazepine-assisted detoxification received placebo, baclofen 30 mg/day, or baclofen 60 mg/day for 7 days, with diazepam supplied as needed according to CIWA-Ar symptoms. ^[77]A1b The study addressed whether baclofen reduced additional diazepam requirements, but the authors concluded that available evidence remained insufficient to support baclofen-assisted withdrawal as routine treatment. ^[77]A1b Magnesium supplementation similarly reflects an attempt to correct physiologic contributors to withdrawal: a multicenter double-blind randomized trial enrolled inpatients with baseline CIWA-Ar scores >8 and compared oral magnesium lactate providing 426.6 mg/day with placebo for up to 15 days. ^[52]A1b

Other proposed benzodiazepine-sparing strategies have produced mixed or limited evidence. A double-blind randomized trial assigned 120 residential-withdrawal patients to vigabatrin 2 g/day for 4 days or placebo, assessing the need for diazepam and total diazepam exposure. ^[78]A1b A randomized sham-controlled trial in men with acute AWS compared transcutaneous electrical acupoint stimulation plus diazepam with diazepam plus sham stimulation for 14 days; both groups improved on CIWA-Ar, visual analogue pain or symptom measures, sleep quality, and sleepiness assessments. ^[60]A1b Dexmedetomidine, an α2-adrenergic sedative, was compared with intravenous diazepam in a randomized trial of 40 patients, with the study focusing on heart rate, blood pressure, and sedation. ^[154] A later retrospective cohort study examined dexmedetomidine versus non-dexmedetomidine treatment in AWS from 2016–2022, evaluating ICU stay, hospital length of stay, mortality, and readmission. ^[69]B3b

Re-emergence of phenobarbital

Phenobarbital has re-entered contemporary AWS practice as either an adjunct to benzodiazepines or an alternative monotherapy. ^[101]D5 ASAM recommends phenobarbital in selected clinical contexts, and current evidence is considered sufficient to demonstrate safety and efficacy as a benzodiazepine alternative, although the overall evidence base remains limited. ^[101]D5 Its long half-life has prompted interest in front-loaded or single-dose approaches that may provide an intrinsic taper. A retrospective ICU cohort compared phenobarbital loading followed by a taper with loading without a taper; the investigators specifically examined whether the drug’s long half-life could support auto-tapering. ^[155]C

Reconsideration of ethanol and disease-specific care

Ethanol itself has periodically been proposed as a treatment because it modulates both GABA-A and NMDA receptors. ^[102]A1a A 2024 systematic review critically evaluated oral and intravenous ethanol for prevention or treatment of AWS, reflecting renewed examination of a historically plausible but nonstandard strategy. ^[102]A1a In UK acute-care practice, oral ethanol prescribing was retrospectively compared with benzodiazepines for patients considered at high risk, including those with a history of delirium tremens, alcohol-related seizures, severe withdrawal, or typically harmful consumption of ≥30 units/day. ^[147]C These data represent implementation experience rather than high-certainty comparative evidence. ^[147]C

Treatment has also become more individualized for medically complex populations. In a multinational retrospective cohort of patients hospitalized with alcohol-associated hepatitis, investigators assessed AWS prevalence, predictors, management, and mortality, including the potential role of prophylaxis. ^[30]B2b Trauma research has similarly examined combinations of admission characteristics to estimate the probability of AWS in hospitalized trauma patients. ^[31]B2b In alcohol-associated hepatitis, delirium tremens may be followed by loss of clinical contact and missed critical events, emphasizing the need for continued monitoring after apparent stabilization. ^[40]C4 Severe withdrawal is also clinically consequential beyond the acute episode: a prospective multicenter cohort found that severe AWS was examined as a factor associated with suicidal acts during 2 years of follow-up among patients treated for AUD. ^[103]B2b

Overall, treatment has progressed from largely symptom-directed benzodiazepine therapy toward protocolized assessment, risk-based monitoring, phenobarbital-based strategies, and selective use of adjunctive agents. ^{[44]A1c[65]A1c[101]D5} Nevertheless, randomized and observational evidence for many alternatives remains limited, and benzodiazepines continue to provide the principal comparator and established framework for preventing severe AWS complications. ^{[70]B2b[77]A1b[101]D5[102]A1a}

Clinical burden and major complications

Alcohol withdrawal syndrome (AWS) ranges from mild autonomic and neuropsychiatric symptoms to seizures, delirium tremens, severe agitation, respiratory compromise, intensive-care admission and death; the severity of the syndrome is clinically important because treatment itself may cause oversedation and other harms. ^{[74]A1a[46]A1a[66]A1a} In a primary-care population, AWS was sufficiently consequential to be evaluated as an important cause and complication of hospitalization, although the supplied abstract does not report the incidence estimate. ^[128]

Risk assessment should be performed early and should incorporate previous complicated withdrawal, current illness, and the reliability of symptom scoring. In a randomized hospital trial, adults with PAWSS ≥4 were considered at risk for complicated withdrawal and were randomized to fixed-dose gabapentin or CIWA-directed benzodiazepines within 16 hours of admission. ^[70]B2b CIWA-Ar-based pathways may be difficult to interpret in patients who cannot communicate reliably or who have concurrent delirium, critical illness, trauma, hepatic encephalopathy, or sedative exposure; a revised MINDS-based protocol was therefore evaluated on a general medical ward rather than only in the ICU. ^[130]

Comorbidity and vulnerable populations

Liver disease substantially complicates AWS management because impaired drug metabolism may increase sedative accumulation, respiratory depression, and encephalopathy risk. ^[142][156] In a retrospective Mayo Clinic cohort, patients with liver disease receiving CIWA-Ar protocols had a high prevalence of alcohol use disorder and a longer hospital stay than patients without liver disease; the supplied abstract reports median stays of 93 hours versus 69 hours, respectively. ^[142] Alcohol-associated hepatitis is another high-risk setting: a multinational retrospective cohort investigated AWS prevalence, predictors, management and mortality, with mortality models adjusted for demographic variables and disease severity. ^[30]B2b

Severe AWS in patients with alcohol-associated liver disease remains an area of therapeutic uncertainty. A retrospective MIMIC-IV ICU cohort compared phenobarbital with benzodiazepines as the initial sedative in patients with alcohol-associated liver disease and severe AWS, using inverse-probability treatment weighting to balance baseline characteristics. The study was designed specifically to evaluate efficacy and safety concerns including oversedation, hepatic encephalopathy and respiratory depression, but the supplied abstract does not provide outcome estimates. ^[156]

Pregnancy and the early postpartum period require particularly cautious management because withdrawal may affect both mother and fetus. In a Mayo Clinic retrospective series, only 8 pregnant patients were identified among records assessed under a CIWA-Ar protocol; their median peak CIWA-Ar score was 17 (interquartile range 14), and pregnancy, labor and neonatal outcomes were reviewed for alcohol-related complications. ^[140]C The small sample limits generalizability and does not establish comparative treatment safety. ^[140]C

Sex and age may influence the observed phenotype and hospital course. A large Mayo Clinic cohort included 16,190 hospitalizations representing 10,092 patients, of whom 30.2% were women; patients were stratified into age groups from 21–39 years through ≥75 years to examine age- and sex-related differences in AWS manifestations and hospitalization. ^[36]B2b In a separate tertiary alcohol-related disease-unit cohort of 907 patients, women comprised 26.2%; the study compared psychiatric and clinical features, including AWS severity, between sexes. ^[125]

Medication-related harm and comparative treatment evidence

Benzodiazepines remain standard therapy, particularly for preventing seizures and delirium tremens, but their adverse effects include oversedation, respiratory depression and potentially delirium; these concerns are especially relevant in liver disease and critical illness. ^{[70]B2b[75]A1a[136][156]} Phenobarbital may be used as an alternative or adjunct when benzodiazepines are insufficient or unavailable, but evidence on optimal dosing, efficacy and safety remains heterogeneous. ^{[74]A1a[46]A1a[66]A1a}

A systematic review of emergency-department studies directly compared phenobarbital with benzodiazepines or no intervention and assessed AWS complications, monitored-setting admission, symptom control, adverse effects and adjunctive medication use. ^[74]A1a A separate systematic review and meta-analysis included randomized and observational ED and ICU studies through 30 June 2022 to compare clinical outcomes of phenobarbital-based treatment with benzodiazepine-based treatment. ^[46]A1a A broader review identified 20 phenobarbital articles—9 from the ED and 11 from other settings—but concluded that the evidence base and appropriate dosing remained unclear. ^[66]A1a

In trauma patients, a retrospective cohort compared benzodiazepine management with a low-dose oral phenobarbital regimen because of concerns about benzodiazepine-associated delirium and refractory withdrawal; patients receiving pre-admission benzodiazepines or barbiturates, or propofol or dexmedetomidine before protocol initiation, were excluded. ^[136] In critically ill surgical-trauma patients, phenobarbital therapy was evaluated for AWS-related complications defined as severe agitation, delirium tremens or seizures after treatment initiation. ^[131] These non-randomized studies cannot reliably separate medication effects from baseline illness severity. ^{[66]A1a[136][131]}

Gabapentin is an evidence-based outpatient option, but its role in hospitalized AWS is less established. ^{[70]B2b[75]A1a} An open-label randomized trial of 88 hospitalized adults at risk for complicated withdrawal compared a fixed-dose gabapentin taper with CIWA-directed benzodiazepines. ^[70]B2b A meta-analysis of 8 retrospective studies involving 2,030 patients found no randomized studies in the included hospitalized evidence base, limiting confidence about whether gabapentin can replace benzodiazepines or prevent serious complications. ^[75]A1a

Dexmedetomidine may reduce apparent autonomic symptoms or CIWA-Ar scores, but it is not established as definitive anticonvulsant or delirium-tremens therapy in the supplied evidence. ^[69]B3b A retrospective cohort from 2016–2022 compared dexmedetomidine-containing and non-dexmedetomidine AWS treatment for ICU stay, hospital stay, mortality and readmission. ^[69]B3b

Systems-related and iatrogenic risk

EHR order sets can propagate unsafe or non-guideline-concordant treatment. A national cross-sectional review of hospital AWS order sets assessed laboratory evaluation, severe-AWS risk assessment, symptom treatment and identification or management of associated problems, demonstrating that protocol design is an important potential source of treatment variation. ^[149] Conversely, symptom-based protocols such as revised MINDS pathways may offer an alternative when CIWA-Ar is unreliable, although their safety and effectiveness require local validation. ^[130]

Patients with AWS often require deep sedation, airway management or ICU monitoring, but sedation-related analyses may exclude AWS and therefore should not be extrapolated directly. A medical-ICU study of intubated patients specifically excluded AWS, seizures and several other indications, so it does not provide direct evidence about sedation depth or medication exposure in AWS. ^[141]C Likewise, a study of ICU admission and mortality during a state-directed lockdown concerned non-COVID ICU admissions rather than AWS-specific treatment harms and should not be interpreted as AWS outcome evidence. ^[145]

Practical safety priorities

Preventable harm is reduced by early recognition of complicated withdrawal, frequent reassessment, appropriate monitoring, cautious dose escalation, attention to hepatic dysfunction and respiratory status, and avoidance of using symptom suppression alone as evidence that the underlying seizure or delirium risk has resolved. ^{[74]A1a[66]A1a[142][156]} Phenobarbital, gabapentin and dexmedetomidine should therefore be considered context-dependent strategies rather than universally safer substitutes for benzodiazepines, because much of the comparative evidence is observational and dosing remains incompletely standardized. ^{[46]A1a[66]A1a[75]A1a[69]B3b}

Clinical course and severity

Alcohol withdrawal syndrome (AWS) has a heterogeneous course: in an emergency-department derivation study, most patients who subsequently developed withdrawal experienced mild symptoms, whereas a smaller proportion developed withdrawal seizures or delirium tremens (DT). ^[137] Severe AWS was defined in that study as a composite of DT, seizure, or high benzodiazepine requirements. ^[137] A machine-learning study similarly attempted to distinguish mild from moderate-to-severe withdrawal and to predict DT and withdrawal seizures using admission clinical, laboratory, and sociodemographic variables. ^[93]B2c These findings support early risk stratification rather than assuming that an initially mild presentation will remain uncomplicated. ^[93]B2c[137]

Withdrawal severity is associated with hospital outcomes. In a retrospective cohort of 2,464 hospital stays, maximum withdrawal scores were categorized as mild (<6), moderate (6–9), or severe (>9); higher maximum scores were analyzed in relation to prolonged length of stay and in-hospital mortality. ^[58]B3b The same study separately examined the maximum score during the first 3 days of withdrawal, emphasizing that early peak severity may have prognostic value. ^[58]B3b A systematic review and meta-analysis evaluated serial CIWA-Ar scores as an objective measure of withdrawal trajectory and compared benzodiazepine with non-benzodiazepine treatment, but the supplied evidence does not provide pooled numerical estimates for symptom resolution or mortality. ^[55]A1a

Predictors and clinically important subgroups

The Alcohol Withdrawal Triage Tool was derived and validated to predict severe AWS using objective information available during an emergency-department assessment, with the primary outcome including DT, seizure, or high benzodiazepine use. ^[137] A separate two-site observational machine-learning analysis used 121 clinical, blood-derived, and sociodemographic variables to predict moderate-to-severe withdrawal, DT, and withdrawal seizures, with out-of-sample validation. ^[93]B2c Together, these studies indicate that prognosis can be informed by admission data, although the supplied evidence does not establish that either model should replace clinical monitoring. ^[93]B2c[137]

Age and sex may modify presentation and hospital course. A 2026 cohort included 16,190 hospitalizations and 10,092 patients managed under a CIWA-Ar protocol; women accounted for 30.2% of patients, and participants were stratified into age groups of 21–39, 40–64, 65–74, and ≥75 years. ^[36]B2b The supplied abstract identifies the study as an investigation of age- and sex-related differences but does not provide the corresponding outcome estimates. ^[36]B2b

Comorbid alcohol-associated hepatitis is an important prognostic context. A multinational retrospective cohort from five centers evaluated the prevalence, predictors, management, and clinical impact of AWS in hospitalized patients with alcohol-associated hepatitis, using mortality as the primary outcome and adjusting multivariable models for demographic variables and disease severity. ^[30]B2b In a separate Japanese retrospective series of 88 patients with alcoholic hepatitis, investigators examined ACLF, DT, risk factors, and patient outcomes; the study highlighted the possibility that loss of contact after DT may lead to missed critical events. ^[40]C4

Treatment-related outcomes

In 6,938 Veterans Health Administration medical inpatients with AWS, initial benzodiazepine strategies were symptom-triggered in 40.8%, fixed-dose in 41.9%, and front-loaded in 17.3%. ^[5]B2c The study evaluated how patient and facility characteristics related to cumulative benzodiazepine exposure, intensive-care admission, and intubation, demonstrating that treatment strategy and clinical setting are relevant to hospital course. ^[5]B2c In severe AWS, an early focused protocol in which more than 50% of total diazepam was administered during the first 24 hours was evaluated in a pre-post cohort; severe AWS was defined by diazepam requirements of >30 mg. ^[172]C The supplied evidence describes the intervention and its intended effect on hospital length of stay but does not provide the numerical outcome estimates.

Evidence for adjunctive therapies remains mixed and generally concerns short-term treatment outcomes rather than long-term prognosis. A network meta-analysis of 41 studies involving 4,187 participants found no significant difference in CIWA-Ar reduction between benzodiazepines and other medication strategies; anticonvulsant plus benzodiazepine therapy was associated with a mean ICU stay difference of −1.71 days (95% CI, −2.82 to −0.59) versus benzodiazepines. ^[57]A1a Randomized studies evaluated oxytocin with symptom-triggered oxazepam over 3 days, baclofen versus chlordiazepoxide over 9 days, vigabatrin over 4 days, transcutaneous electrical acupoint stimulation with diazepam over 14 days, and dexmedetomidine added to benzodiazepines in the ICU. ^{[81]A1b[107]A1b[78]A1b[60]A1b[170]} These studies primarily assessed symptom scores, benzodiazepine exposure, sedation, or treatment efficacy and do not establish durable effects on relapse, recurrent withdrawal, or mortality. ^{[81]A1b[107]A1b[78]A1b[60]A1b[170]}

Phenobarbital evidence is concentrated in critically ill or treatment-escalated patients. A 2026 systematic review and meta-analysis compared phenobarbital-based with benzodiazepine-based pathways in critically ill adults and specifically examined whether pathway design and timing influenced outcomes. ^[169] A multicenter propensity-matched cohort evaluated real-world phenobarbital use as a marker of severe or refractory AWS and treatment escalation, including time to discharge and safety outcomes. ^[171] Retrospective studies also compared phenobarbital combinations with benzodiazepine monotherapy or dexmedetomidine-based adjunctive treatment, assessing AWS resolution, length of stay, mechanical ventilation, and treatment-related harm. ^{[126][114]B3b} Because these studies are observational or focus on selected ICU populations, their associations should not be interpreted as proof that phenobarbital itself causes better or worse prognosis. ^{[126][114]B3b[171]}

Prognostic interpretation

The strongest consistent prognostic signal in the supplied evidence is peak withdrawal severity, particularly the occurrence of seizures or DT and high sedative requirements. ^{[58]B3b[93]B2c[137]} ICU admission, intubation, mechanical ventilation, and length of stay are commonly used markers of severe or refractory disease, but treatment selection may itself reflect baseline severity and confound comparisons between regimens. ^{[5]B2c[114]B3b[126][171]} Patients with severe scores, rapidly escalating medication requirements, suspected seizures or DT, significant liver disease, or difficulty maintaining observation require close reassessment because clinically important deterioration may be missed when follow-up is interrupted. ^{[30]B2b[40]C4[58]B3b[137]}

Scope and evidence limitations

Alcohol withdrawal syndrome (AWS) in pregnancy and the early postpartum period requires urgent medical, obstetric, fetal, and psychiatric assessment because evidence specific to this population is sparse. ^[140]C The principal pregnancy-focused study identified only 8 pregnant patients among Mayo Clinic patients managed using a Clinical Institute Withdrawal Assessment for Alcohol–Revised (CIWA-Ar) protocol between June 2019 and June 2022. ^[140]C In that series, withdrawal was clinically substantial, with a median peak CIWA-Ar score of 17 and an interquartile range of 14. ^[140]C These data support treating pregnancy-associated AWS as potentially severe rather than assuming that pregnancy protects against complicated withdrawal. ^[140]C

The strongest pharmacological evidence is not pregnancy-specific: a systematic review included 24 randomized controlled trials and 2,223 adults aged >18 years, identified through March 2020. ^[110]A1a Consequently, efficacy and safety estimates for anticonvulsants cannot be directly extrapolated to the fetus, neonate, pregnancy, or postpartum period. ^[110]A1a The same limitation applies to recent observational studies of phenobarbital, benzodiazepines, dexmedetomidine, and other AWS regimens, which evaluated adult hospital or intensive-care populations rather than pregnant patients. ^{[111]B3b[113]B3b[114]B3b[155]C[161][162][171]}

Pregnancy and early postpartum management

Pregnant or recently postpartum patients with suspected AWS should receive a low threshold for hospital-level assessment, with coordinated obstetric, addiction, psychiatric, and critical-care input when symptoms are moderate, severe, atypical, or rapidly progressive. ^[140]C The available pregnancy series specifically examined patients undergoing CIWA-Ar-based care and documented high withdrawal severity, but its small sample prevents reliable estimates of maternal, fetal, labor, or neonatal risk. ^[140]C CIWA-Ar should therefore support, rather than replace, repeated clinical assessment, because withdrawal symptoms may overlap with obstetric illness, infection, medication effects, metabolic abnormalities, or other causes of agitation and autonomic instability. ^[140]C[163]

Benzodiazepines remain the comparator and contemporary treatment standard in the adult AWS evidence base, but the systematic review does not establish pregnancy-specific fetal or neonatal safety. ^[110]A1a If medication is required during pregnancy, clinicians should use the minimum effective exposure within a monitored protocol and involve obstetric and neonatal clinicians; the available references do not support declaring an anticonvulsant or phenobarbital regimen the preferred treatment in pregnancy. ^{[110]A1a[140]C} Phenobarbital has been studied in adult emergency, ward, and ICU populations, including as monotherapy, as an adjunct to lorazepam, and with or without a taper, but these studies do not provide pregnancy-specific safety evidence. ^{[113]B3b[114]B3b[155]C[161][162][171]}

Maternal stabilization remains the immediate priority when severe withdrawal, seizures, delirium, or cardiorespiratory compromise occurs, while fetal assessment and neonatal planning proceed in parallel. ^[140]C The available pregnancy study indicates that both pregnancy and early postpartum AWS can be associated with clinically important maternal and fetal outcomes, but the supplied abstract does not provide sufficient event-level detail to quantify those risks. ^[140]C

Perinatal psychiatric and diagnostic considerations

Perinatal psychiatry assessment should address alcohol use disorder, previous withdrawal seizures or delirium, suicidality, trauma, mood and anxiety disorders, psychosis, safeguarding, social support, and the safety of the pregnant or postpartum patient and infant; the provided studies establish the need for multidisciplinary assessment but do not quantify these psychiatric comorbidities. ^[140]C Screening and treatment planning should continue after acute withdrawal because hospitalization for AWS represents an opportunity to identify ongoing alcohol-related risk and connect the patient with addiction and mental-health care. ^{[127][128][143]}

Do not attribute delirium, seizures, fever, or altered consciousness automatically to AWS. ^[48]B2b[163] In a prospective population-based study of bacterial meningitis, 18% of alcoholic patients presented with seizures and 23% had coexisting pneumonia, demonstrating important infectious differentials in patients with alcohol-related illness. ^[48]B2b Postoperative patients may also be misclassified: a prospective study evaluated the false-positive rate of CIWA-Ar after major abdominal surgery because postoperative physiology and systemic inflammatory response syndrome overlap with AWS manifestations. ^[163] These concerns are particularly important in pregnancy and postpartum care, where hypertensive, infectious, hemorrhagic, thromboembolic, metabolic, and neurologic disorders may present with agitation, seizures, or altered mental status. ^[140]C

Medical comorbidity and supportive care

Nutritional and metabolic abnormalities should be actively assessed in all high-risk patients. ^[157][158]C In a retrospective AWS cohort, 17% of analyzed patients had died at 1 year, and low serum magnesium was investigated as a prognostic factor. ^[157] Patients with alcohol use disorder admitted to an intensive-care unit were also evaluated for vitamin C deficiency, supporting attention to micronutrient depletion in addition to established thiamine replacement practice. ^[158]C These observational findings do not establish that magnesium or vitamin C supplementation prevents withdrawal complications, and pregnancy-specific dosing evidence was not provided. ^[157][158]C

Symptom-triggered treatment may be feasible in closely monitored settings: an emergency-department short-stay study reported that 5% (174/3,222) of admissions required symptom-triggered therapy. ^[159]C However, symptom-triggered protocols require reliable assessment and trained staff; severe illness, delirium, sedation, postoperative states, neurologic disease, or obstetric complications may make CIWA-Ar-based dosing unreliable. ^{[140]C[159]C[161][163]}

Evidence gaps

Recent national and multicenter studies describe substantial variation in adult AWS treatment and increasing use of phenobarbital, but they do not resolve medication selection during pregnancy or lactation. ^{[111]B3b[113]B3b[114]B3b[127][171]} Pregnancy-specific prospective research is needed on maternal stabilization, fetal effects, neonatal adaptation, breastfeeding, psychiatric outcomes, and comparative benzodiazepine versus anticonvulsant or phenobarbital strategies. ^{[110]A1a[140]C}

Prevention framework

Alcohol withdrawal syndrome (AWS) is potentially life-threatening and is associated with prolonged hospitalization and recurrent alcohol-related admissions, making prevention through early recognition and risk-stratified intervention clinically and economically important. ^[72]B2a A 2024 primary-care cohort found that hospitalization involving AWS could be evaluated in a population receiving standardized annual alcohol screening with the Alcohol Use Disorders Identification Test (AUDIT), supporting systematic identification of unhealthy alcohol use before an acute admission. ^[128] Alcohol use and alcohol use disorder are also relevant in trauma populations, where admission blood alcohol concentration, documented alcohol use disorder, and AWS may be associated with unplanned hospital events. ^[112]B3b

Prevention should include asking about alcohol quantity and frequency, prior withdrawal episodes, withdrawal seizures or delirium, recent reduction or cessation, prior detoxification, concurrent sedative use, and medical or psychiatric comorbidity. These domains are supported by studies examining risk conditions in acute-hospital and trauma populations, although the specific predictors and their relative importance vary between cohorts. ^{[31]B2b [35]B3b [50]B2a} Older adults may require particular vigilance because alcohol use and alcohol use disorder are being evaluated in relation to in-hospital complications among people aged ≥80 years. ^[160]

Screening for withdrawal risk

The Alcohol Use Disorders Identification Test–Piccinelli Consumption (AUDIT-PC) has been studied as an admission tool for predicting AWS among hospitalized medical-surgical patients outside intensive care. ^[8]B3b However, AUDIT-PC is an alcohol-consumption screen rather than a validated severity-prediction instrument, and screening should be followed by clinical assessment and serial observation. ^[8]B3b

The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) was developed because commonly used withdrawal-severity instruments, such as the Clinical Institute Withdrawal Assessment for Alcohol (CIWA), quantify symptoms after withdrawal begins but do not identify patients at risk in advance. ^[50]B2a PAWSS was designed to predict complicated, moderate-to-severe AWS in medically ill patients and to support timely prophylaxis, although the cited publication describes a systematic review and pilot validation rather than definitive universal validation. ^[50]B2a

Risk assessment is particularly important in trauma and critical-care settings. A trauma-center retrospective study evaluated heavy drinking, defined as daily drinking or >7 drinks per week, together with other admission characteristics to estimate the probability of AWS. ^[31]B2b In the intensive-care population, a systematic review examined prevalence, risk factors, screening tools, prophylactic strategies, treatment strategies, and outcomes for AWS and delirium tremens, while noting the absence of established practice guidelines specific to critically ill patients. ^[115]A1a

Machine-learning models have also been investigated using admission clinical, laboratory, and sociodemographic variables to distinguish mild from moderate-to-severe withdrawal and to predict delirium tremens and withdrawal seizures. ^[93]B2c These approaches may augment—not replace—clinical judgment, because the cited work was observational and model performance does not itself establish clinical benefit. ^[93]B2c

Hospital early-intervention protocols

A practical hospital pathway is universal alcohol-use screening, formal risk assessment with PAWSS or another structured instrument, serial symptom assessment, and protocolized treatment escalation. ^[143] In one retrospective hospital evaluation, universal screening of non-critical-care admissions with PAWSS was followed by Glasgow Modified Alcohol Withdrawal Scale assessment and medication according to a predetermined protocol; the study examined length of stay, benzodiazepine exposure, and AWS-related adverse events. ^[143] Electronic health-record order sets can standardize laboratory assessment, severe-withdrawal risk assessment, symptom monitoring, treatment, and prevention of omissions, but a multicenter review found variation in guideline concordance between hospital organizations. ^[149]

Patients with a history or current features suggesting complicated withdrawal should not be managed as low-risk ambulatory cases. Risk stratification should determine observation intensity, readiness for prophylaxis, and the need for monitored or intensive-care treatment, particularly when delirium, seizures, severe autonomic instability, serious medical illness, or inability to ensure follow-up is present. ^{[50]B2a [115]A1a}

Pharmacologic early intervention and ambulatory detoxification

Benzodiazepines remain a principal evidence-supported treatment class for clinically significant AWS; a randomized, double-blind inpatient comparison evaluated fixed-dose lorazepam 8 mg/day versus chlordiazepoxide 80 mg/day, each down-titrated to zero over 8 treatment days, in men with moderately severe uncomplicated withdrawal. ^[116]A1b The trial directly addressed comparative efficacy, symptom control, and impairing adverse events, but its inpatient male sample limits generalization to medically complex, outpatient, or older populations. ^[116]A1b

Ambulatory detoxification requires eligibility screening, daily or otherwise reliable monitoring, rapid access to rescue care, and exclusion of high-risk withdrawal. Open-label outpatient studies evaluated levetiracetam alone at flexible doses of 500–4,000 mg/day for up to 7 days, with diazepam available as rescue medication, and levetiracetam combined with tiapride at doses up to 2,500 mg/day and 300 mg/day, respectively, for a maximum of 7 days. ^{[165] [117]C4} These small observational or case-series evaluations reported feasibility and completion in selected patients, but they do not establish superiority over benzodiazepines or support routine use for high-risk AWS. ^{[165] [117]C4}

Cochrane reviews assessed baclofen for AWS but provide evidence from a limited historical literature base; baclofen should therefore not be substituted for established monitored treatment without specialist justification. ^{[13]A1a [14]A1a} A later pilot case series evaluated a fixed-dose 6-day gabapentin taper, from 1,800 mg to 300 mg, in patients selected as low risk by validated criteria and followed by telemedicine and in-person or virtual review. ^[166]C Its small retrospective design supports protocol feasibility only, not broad efficacy or safety conclusions. ^[166]C

Economic evidence remains limited: a 2025 systematic review identified 8 eligible studies from 6,347 records, indicating a small evidence base for comparing the costs and outcomes of AWS-management strategies. ^[72]B2a Accordingly, prevention should prioritize validated risk recognition, appropriate monitoring, standardized protocols, and prompt escalation rather than relying on unvalidated outpatient medication regimens. ^{[72]B2a [50]B2a}